IBRX - one of the most shorted stocks on the market just got FDA approval for a breakthrough cancer drug

- ImmunityBio (IBRX) is a biotech company focusing on cures for cancer - FDA has granted approval for their new drug Anktiva, a significant breakthrough in battling bladder cancer - 40% of the company's stock is currently being shorted - A rare opportunity for traders with the new immunotherapy drug on the market - Link to press release: [https://finance.yahoo.com/news/immunitybio-announces-fda-approval-anktiva-015600720.html](https://finance.yahoo.com/news/immunitybio-announces-fda-approval-anktiva-015600720.html)